Fatigue is characterized by three major aspects: physiological effects, psychological effects, and disease \[[@r2]\]. Physical fatigue is commonly associated with elevated stress levels caused by a modern lifestyle, and is also related to the exercise-reduced maximal force-generating capacity of muscle \[[@r46]\]. It alters performance, leading to decreased muscular power and endurance, decreased motor skill performance, and diminished physical and mental function \[[@r39]\]. The exhaustion theory suggests that during exercise, many energy sources, such as glucose and liver glycogen, will be exhausted, leading to physical fatigue \[[@r37]\]. Other biomarkers, such as lactate, ammonia, blood urea nitrogen (BUN), and glucose, are also widely used to evaluate fatigue \[[@r20], [@r35]\]. Regular exercise improves the body's functionality, but strenuous sports are responsible for the accumulation of reactive oxygen and lipid peroxides, which damage organs and also lead to fatigue \[[@r22], [@r32]\]. Fatigue is worthy of attention, as it may cause various disorders related to the bio-regulatory and immune systems. These disorders also cause reductions in exercise intensity, or even interruption of activity \[[@r33]\].

*Arctium lappa*, known as "Niubang" in Chinese, has been used in China and some western countries for over 3,000 years. Its therapeutic uses have been documented in The Compendium of Materia Medica (Bencao Gangmu in Chinese) written in the Ming Dynasty by Li Shizhen, the most important and famous figure in the history and development of traditional Chinese medicine \[[@r45]\]. Commonly known as burdock (BD), this plant is promoted as a healthy and nutritive food in Chinese societies. It is a perennial herb in the Compositae family, storing most of its nutrients during its first year of growth. Many studies have confirmed that BD has antitumor \[[@r3]\], antioxidative \[[@r29]\], anti-inflammatory \[[@r24]\], antibacterial \[[@r43]\], prebiotic \[[@r26]\], and anti-HIV properties \[[@r41]\], inhibits NO production \[[@r30]\], and prevents diabetic complications \[[@r42]\]. BD has also been demonstrated to have many other beneficial effects on health and disease prevention.

However, few studies have directly addressed the effect of BD on physiological fatigue. Our present study aims to use *in vivo* tests in mice to explore whether a drink containing BD, taken after exercise, can delay fatigue, reduce recovery time, improve athletic performance, with minimal toxic effects, promoting the use of such supplements in sports. Therefore, we evaluated the potential ergogenic and anti-fatigue effects of BD by using our previously established *in vivo* platform \[[@r18], [@r20], [@r21]\].

MATERIALS AND METHODS {#s1}
=====================

Materials
---------

BD supplement, a brown color liquid with a characteristic odor, was purchased from Kagro Biotech. Co., Ltd. (Kaohsiung, Taiwan) and provided by Professor Fu-An Chen (Tajen University, Taiwan). BD was prepared using good manufacturing practice and hazard analysis and critical control point-qualified manufacturing. To ensure precise and accurate dosing of animals, heat-sterilized BD extract was lyophilized by freeze-drying to obtain a powder extract. The crude powder extract was stored at −80°C until use. In this study, the human BD dose was 1.7 g/day (as lyophilized powder), equivalent to a daily recommended dose of 200 m*l* water/day. The mouse BD dose (348.5 mg/kg) was calculated from the human equivalent dose (HED) based on body surface area, using the following formula from the US Food and Drug Administration, assuming a human body weight of 60 kg: HED of 1.7 g/60 kg body weight=0.02833 g/kg. Therefore, 0.02833 g/kg × 12.3=a mouse dose of 348.5 mg/kg. A conversion coefficient of 12.3 was used to account for differences in body surface area between mice and humans, as we described previously \[[@r11]\].

Analysis of total BD polyphenol content was performed spectrophotometrically, using a Folin-Ciocalteu reagent based on a colorimetric redox reaction \[[@r15]\]. BD antioxidant activity was estimated from 1,1-diphenyl-2-picrylhydrazyl (DPPH) radical scavenging activity \[[@r5], [@r10]\]. Hazardous chemical contaminants (pesticide residues and heavy metals) and biological contaminants were determined by a Taiwan Food and Drug Administration (TFDA) accredited company (ABM International Lab Inc. Pingtung, Taiwan).

Specifications from the BD certificate of analysis for total polyphenol content and antioxidant activity were ≥150 *µ*g/m*l* and ≥70% DPPH-scavenging activity, respectively. Release limits of 310 pesticide residues and five heavy metals (Pb, Cd, Hg, Cu and As) were all undetectable. Regarding microbiological analysis: total plate counts, and counts for yeast and mold, *E. coli*, *Pseudomonas aeruginosa*, *Staphylococcus aureus* and *Salmonella* spp., all met TFDA criteria.

Animals and treatment
---------------------

We purchased male specific pathogen-free ICR mice (6 weeks old), from BioLASCO (A Charles River Licensee Corp., Yi-Lan, Taiwan). Experimental animals were given 2 weeks to acclimatize to the environment and diet. All animals were provided with a standard laboratory diet (No. 5001; PMI Nutrition International, Brentwood, MO, U.S.A.) and distilled water *ad libitum*, and maintained at a regular light cycle (12-hr light/dark), at room temperature (24 ± 2°C) and 60--70% humidity. Bedding was changed and cleaned twice per week. All animal experiments conformed to the Institutional Animal Care and Use Committee (IACUC) of the National Taiwan Sport University, and the study conformed to guidelines in the protocol IACUC-10309 approved by the IACUC ethics committee.

Animals were randomly separated into four groups (10 mice/group) for oral gavage treatment once a day for 4 weeks: (1) vehicle (distilled water); (2) 348.5 mg/kg BD (BD-1X); (3) 697 mg/kg BD (BD-2X); and (4) 1,742.5 mg/kg BD (BD-5X). The vehicle group received the same volumes of solution as the BD groups, calculated based on individual body weight (BW), and received the vehicle at a constant dosage volume of 10 m*l*/kg throughout the treatment period. Food intake and water consumption were monitored daily, and BW was recorded weekly.

Forelimb grip strength
----------------------

We used a low-force testing system (Model-RX-5, Aikoh Engineering, Nagoya, Japan) to measure forelimb grip strength, as previously described \[[@r18], [@r21], [@r35]\].

Swimming exercise performance test
----------------------------------

Mice were pretreated with the vehicle, or 348.5, 697, or 1,742.5 mg BD/kg for 28 continuous days, followed by an exhaustive swimming test commencing 1 hr after the last treatment. Details of the swimming exercise in the forced swimming test were as previously described, to evaluate endurance \[[@r21], [@r35]\]. The swim-to-exhaustion exercise test involved mice carrying constant loads corresponding to 5% BW. The swimming endurance time was recorded from the start of the test to exhaustion, determined by observing loss of coordinated movements and failure to return to the surface within 7 sec.

Determination of fatigue-associated biochemical variables
---------------------------------------------------------

The effects of BD on the following fatigue-associated biochemical indices were evaluated post exercise: serum lactate, ammonia, glucose, creatine kinase (CK), and BUN activity. Mice underwent a 15-min swimming test without weight loading, 1 hr after the last treatment. Blood samples were then immediately collected from the submandibular duct of pretreated mice, and then centrifuged at 1,500 ×g and 4°C for 10 min for serum preparation \[[@r20], [@r35]\]. Serum lactate, ammonia, glucose, CK and BUN levels were determined on the same day, using an autoanalyzer (Hitachi 7060, Hitachi, Tokyo, Japan).

Tissue glycogen determination
-----------------------------

Glucose is stored as glycogen, which mostly exists in the liver and muscle tissues. The mice were pretreated with vehicle, BD-1X, BD-2X and BD-5X for 28 continuous days. All mice were killed 1 hr after the last treatment. After blood collection and sacrifice, the liver and muscle tissues were excised and weighed for glycogen content analysis.

Glycogen analysis was performed as previously described, with some modifications \[[@r21]\]. For each mouse, 100 mg of liver and muscle was finely cut, weighed, and homogenized in 0.5 m*l* cold 10% perchloric acid. After centrifugation for 15 min at 15,000 ×g and 4°C, the supernatant was carefully decanted and incubated on ice for analysis. Standard glycogen (Sigma) or tissue extract (30 *µl*) was added to 96-well micro-plates, and 200 *µl* iodine-potassium iodide reagent was added to each well to measure iodine binding to glycogen. An amber-brown compound developed immediately after the reaction. An ELISA reader (Tecan Infinite M200, Tecan Austria, Salzburg, Austria) with wavelength 460 nm was used to measure the absorbance after resting the material for 10 min \[[@r38]\].

Histological staining of tissues
--------------------------------

Tissues were collected (liver, kidney, heart and muscle), weighed, and immediately fixed in 10% formalin. Heart tissue was cut transversely to obtain ventricular sections and four-chamber cross-sections, and the liver and muscle tissues (soleus) were minced, embedded in paraffin, and then stained with hematoxylin and eosin (H&E). Tissues were then examined under a light microscope equipped with a CCD camera (BX-51, Olympus, Tokyo, Japan) by a veterinary pathologist \[[@r21]\].

Statistical analysis
--------------------

All data are expressed as mean ± SEM. Differences between groups were analyzed by one-way ANOVA and the Duncan test, to test for significant differences between the treatment groups. The Cochran-Armitage test for dose-effect trend analysis was also used, with SAS 9.0 software (SAS Inst., Cary, NC, U.S.A.). Values for *P*\<0.05 were considered statistically significant.

RESULTS {#s2}
=======

Subacute toxicity of BD supplementation with general characteristics
--------------------------------------------------------------------

We evaluated the general characteristics of the mice and subchronic toxic effects of BD supplementation, by observing behavior, food consumption, growth curves, organ weight, and histopathology. BW was unaltered in all groups over the duration of 4 weeks ([Fig. 1](#fig_001){ref-type="fig"}Fig. 1.The effect of BD supplementation on growth. Data are mean ± SEM, n=10.). In addition, daily intake of diet and water did not differ in the vehicle and BD treatment groups. Organ weights, including the liver, muscle, kidney, testis, epididymal fat pad (EFP), and brown adipose tissue (BAT), did not differ between groups ([Table 1](#tbl_001){ref-type="table"}Table 1.General characteristics of the experimental groupsCharacteristicVehicleBD-1XBD-2XBD-5XTrend analysisInitial BW (g)30.5 ± 0.330.0 ± 0.330.1 ± 0.230.4 ± 0.30.8597Final BW (g)38.5 ± 0.738.3 ± 0.538.2 ± 0.338.3 ± 0.30.4544Food intake (g/mouse/day)6.2 ± 0.1^a,b)^6.4 ± 0.1^b)^6.4 ± 0.2^b)^6.0 ± 0.1^a)^0.3241Water intake (m*l*/mouse/day)8.3 ± 0.38.6 ± 0.38.6 ± 0.38.2 ± 0.30.6170Liver (g)1.99 ± 0.051.98 ± 0.031.98 ± 0.042.00 ± 0.030.8300Muscle (g)0.39 ± 0.010.39 ± 0.010.39 ± 0.010.40 ± 0.010.4304Kidney (g)0.59 ± 0.010.59 ± 0.020.59 ± 0.010.59 ± 0.010.9820Heart (g)0.21 ± 0.010.22 ± 0.010.22 ± 0.010.22 ± 0.010.4464Lung (g)0.29 ± 0.020.30 ± 0.010.30 ± 0.010.30 ± 0.020.7800EFP (g)0.51 ± 0.040.51 ± 0.040.52 ± 0.040.54 ± 0.040.3095Relative liver weight (%)5.17 ± 0.095.19 ± 0.145.20 ± 0.105.21 ± 0.080.7025Relative muscle weight (%)1.01 ± 0.021.01 ± 0.031.01 ± 0.031.01 ± 0.020.2564Relative kidney weight (%)1.55 ± 0.051.53 ± 0.051.55 ± 0.021.55 ± 0.030.7361Relative heart weight (%)0.56 ± 0.020.59 ± 0.020.57 ± 0.010.58 ± 0.020.3909Relative lung weight (%)0.75 ± 0.040.77 ± 0.030.79 ± 0.030.79 ± 0.040.6889Relative EFP weight (%)1.32 ± 0.091.31 ± 0.161.35 ± 0.101.40 ± 0.070.3838Data are mean ± SEM, n=10. Data in the same line followed by different letters \[a or b\] differ significantly with *P*\<0.05, determined by one-way ANOVA. Vehicle: water; BD-1X: 348.5 mg/kg BD; BD-2X: 697 mg/kg BD; BD-5X: 1,742.5 mg/kg BD; EFP: epididymal fat pads.).

Effect of BD supplementation on forelimb grip strength
------------------------------------------------------

Forelimb grip strength is a routine physical examination test. As shown in [Fig. 2A](#fig_002){ref-type="fig"}Fig. 2.Effect of BD supplementation on forelimb grip strength. (A) grip strength; (B) relative grip strength. Data are mean ± SEM, n=10. Bars with different letters (a, b, c) are significantly different with *P*\<0.05, determined by one-way ANOVA. Vehicle (water); 348.5 mg/kg BD (BD-1X); 697 mg/kg BD (BD-2X); 1,742.5 mg/kg BD (BD-5X)., BD-1X, BD-2X and BD-5X treatments significantly increased forelimb grip strength by 1.26-, 1.23- and 1.37-fold (all *P*\<0.0001), respectively, compared to vehicle treatment. Therefore, we divided grip strength by BW to determine relative grip strength, and still found higher grip strength for BD-treated groups than for vehicle groups ([Fig. 2B](#fig_002){ref-type="fig"}), with significant trend findings.

Effect of BD supplementation on exhaustive swimming test
--------------------------------------------------------

Exercise endurance is an important variable in evaluating anti-fatigue treatment. A key indicator to assess the efficacy of anti-fatigue treatment is exercise endurance ability, determined by an exhaustive swimming test ([Fig. 3](#fig_003){ref-type="fig"}Fig. 3.Effect of BD supplementation on exhaustive swimming test. Data are mean ± SEM, n=10. Bars with different letters (a, b) are significantly different with *P*\<0.05, determined by one-way ANOVA.). BD-1X, BD-2X and BD-5X treatments significantly increased swimming time by 1.90- (*P*=0.0365), 2.09- (*P*=0.0124) and 2.53-fold (*P*=0.0007), respectively, compared to vehicle treatment. In the trend analysis, maximal swimming time increased with BD treatment, in a dose-dependent manner (*P*\<0.0001).

Effect of BD supplementation on exercise fatigue-related indicators after acute exercise
----------------------------------------------------------------------------------------

The status of muscle fatigue after exercise can be evaluated by key biochemical indicators, including lactate, ammonia, glucose, and BUN \[[@r17], [@r21], [@r28]\]. We found that vehicle treatment increased serum lactate levels by approximately 29.0% (*P*=0.0005), 35.6% (*P*\<0.0001) and 32.4% (*P*=0.0001), compared to BD-1X, BD-2X and BD-5X treatments, respectively, after acute exercise challenge ([Fig. 4A](#fig_004){ref-type="fig"}Fig. 4.Effect of BD supplementation on serum (A) lactate; (B) ammonia; (C) glucose; (D) creatine kinase (CK) and (E) blood urea nitrogen (BUN) levels after acute exercise challenge. Data are mean ± SEM, n=10. Bars with different letters (a, b) are significantly different with *P*\<0.05, determined by one-way ANOVA.). BD-1X, BD-2X and BD-5X treatments decreased serum ammonia levels, by 23.7, 30.9 and 22.8% (all *P*\<0.0001), respectively, compared to vehicle treatment ([Fig. 4B](#fig_004){ref-type="fig"}). BD-2X and BD-5X treatment increased post-exercise serum glucose levels by 1.20- (*P*=0.0023) and 1.22-fold (*P*=0.0009), respectively, compared to vehicle treatment ([Fig. 4C](#fig_004){ref-type="fig"}). BD-1X treatment slightly increased blood glucose levels compared to vehicle treatment, however, this was not a significant difference compared to either the vehicle or the other BD treatments (*P*\>0.05). BD-1X, BD-2X and BD-5X treatments decreased CK levels by 16.7- (*P*=0.0005), 21.5- (*P*\<0.0001) and 15.6-fold (*P*=0.0009), respectively, compared to vehicle treatment ([Fig. 4D](#fig_004){ref-type="fig"}). BD-1X, BD-2X, and BD-5X treatments significantly decreased BUN levels by 16.7- (*P*=0.0005), 21.5- (*P*\<0.0001) and 15.6-fold (*P*=0.0009), respectively, compared to vehicle treatment ([Fig. 4E](#fig_004){ref-type="fig"}).

Effect of BD supplementation on tissue glycogen level
-----------------------------------------------------

The three levels of BD supplementation increased hepatic glycogen levels by 1.45- (*P*=0.0050), 1.48- (*P*=0.0028), and 1.52-fold (*P*=0.0014), respectively, compared to vehicle treatment ([Fig. 5A](#fig_005){ref-type="fig"}Fig. 5.Effect of BD supplementation on hepatic and muscle glycogen level. Data are mean ± SEM, n=10. Bars with different letters (a, b) are significantly different with *P*\<0.05, determined by one-way ANOVA.). BD-2X and BD-5X treatments increased post-exercise muscle glycogen levels by 1.28- (*P*=0.0207) and 1.32-fold (*P*=0.0079), compared to vehicle treatment ([Fig. 5B](#fig_005){ref-type="fig"}). Post-exercise muscle glycogen levels were significantly different between BD-2X and BD-5X treatments, but BD-1X treatment did not induce a significant difference in glycogen levels, compared to either the vehicle or the other BD groups. Muscle glycogen levels did increase in the BD-1X group compared to the vehicle group, however, this was not a significant difference (*P*\>0.05).

Subacute toxicity of BD supplementation with biochemistry and histopathology evaluation
---------------------------------------------------------------------------------------

In [Table 2](#tbl_002){ref-type="table"}Table 2.Biochemical analysis of vehicle and BD treatment groups at the end of the experimentParameterVehicleBD-1XBD-2XBD-5XTrend analysisUA (mg/d*l*)1.21 ± 0.09^b)^0.92 ± 0.08^a)^0.97 ± 0.03^a)^0.91 ± 0.08^a)^0.0165BUN (mg/d*l*)24.9 ± 1.2^b)^22.9 ± 0.6^a)^22.1 ± 0.8^a)^22.1 ± 0.5^a)^0.0260TC (mg/d*l*)141 ± 5135 ± 3136 ± 5136 ± 70.7251TG (mg/d*l*)154 ± 5130 ± 5136 ± 7132 ± 140.2516LDH (U/*l*)346 ± 29^b)^319 ± 23^a,b)^298 ± 27^a,b)^273 ± 21^a)^0.0288AST (U/*l*)79 ± 7^b)^77 ± 4^b)^62 ± 3^a)^59 ± 2^a)^\<0.0001ALT (U/*l*)46 ± 3^b)^42 ± 2^b)^34 ± 2^a)^35 ± 2^a)^\<0.0001ALK-P (U/*l*)62 ± 352 ± 555 ± 456 ± 40.4712CPK (U/*l*)208 ± 51^b)^200 ± 21^b)^173 ± 28^a,b)^102 ± 24^a)^0.0047ALB (g/d*l*)3.4 ± 0.04^a)^3.44 ± 0.07^a)^3.53 ± 0.04^a,b)^3.62 ± 0.11^b)^\<0.0001TP (g/d*l*)4.8 ± 0.0^a)^4.8 ± 0.1^a)^4.9 ± 0.1^a)^5.1 ± 0.0^b)^\<0.0001CREA (mg/d*l*)0.15 ± 0.010.15 ± 0.010.14 ± 0.010.14 ± 0.010.0572GLU (mg/d*l*)170 ± 7163 ± 7166 ± 5168 ± 40.9791Data are mean ± SEM, n=10. Values in the same row with different superscript letters (a, b) differ significantly with *P*\<0.05, determined by one-way ANOVA. UA: uric acid; BUN: blood urea nitrogen; TC: total cholesterol; TG: triacylglycerol; LDH: lactate dehydrogenase; AST: aspartate aminotransferase; ALT: alanine aminotransferase; ALK-P: alkaline phosphatase; CPK: Creatine phosphokinase; ALB: albumin; TP: total protein; CREA: Creatinine; GLU: glucose., vehicle and BD-1X treatments increased AST and ALT levels compared to BD-2X and BD-5X supplementation. Regarding kidney function: the biochemistry of urea, creatinine, and uric acid (UA) can reflect renal damage. However, vehicle treatment increased serum UA levels by 1.32- (*P*=0.0088), 1.25- (*P*=0.0279) and 1.33-fold (*P*=0.0069), and increased BUN levels by 1.12- (*P*=0.0292), 1.13- (*P*=0.0214) and 1.13-fold (*P*=0.0242), compared to BD-1X, BD-2X and BD-5X treatments, respectively ([Table 2](#tbl_002){ref-type="table"}).

In addition, no differences were observed between the four groups (Vehicle, BD-1X, BD-2X and BD-5X) according to histological observations of the liver, muscle, heart, kidney, lung, and epididymal fat pad. Thus, BD was not harmful, regardless of the administered dosage ([Fig. 6](#fig_006){ref-type="fig"}Fig. 6.Effect of BD supplementation on morphology of (A) liver; (B) skeletal muscle; (C) heart; (D) kidney; (E) lung; and (F) epididymal fat pad in mice. Specimens were photographed by light microscopy (H&E stain, magnification: ×200; Scale bar, 40 *µ*m).).

DISCUSSION {#s3}
==========

Safety is a concern when considering the use of specific extracts or herbs as plant-derived nutritional, medicinal or health-care products. However, limited toxicological reference is available regarding their safety. We assessed the subacute toxic effects of BD by observing mouse behavior, weight (growth), food consumption, organ weight, clinical biochemistry, and histopathology, after 28-day BD repeated-dose supplementation. Previously, BD toxicity did not result in any significant treatment-related changes in behavior, weight, food consumption, organ weight, hematology, clinical biochemistry, and urinalysis \[[@r12]\]. In this study, the no-observed-adverse-effect level of BD could provide optimized dosages for physiological benefit without risk to health, for pursuing the preservation of health.

Forelimb grip strength is a routine physical examination test that reflects the overall health of the musculoskeletal system, and can also be used to evaluate motor-associated coordination and adaption in neurological studies \[[@r1]\]. Previous study has shown a positive correlation between grip strength and anthropometric factors such as age, weight, body mass index, and waist circumference \[[@r8]\]. Our previous study showed that muscle strength positively correlated with forelimb grip strength \[[@r16]\]. In this study, we found the grip of the BD-5X group was greater than the other groups. Therefore, the results indicated that long-term BD supplementation could benefit grip strength when no training protocol is implemented. Our previous reports have shown that long-term supplementation with polyphenols, such as resveratrol and curcumin, also improves the grip strength of untrained animals \[[@r20], [@r21]\].

Our experimental results ([Fig. 3](#fig_003){ref-type="fig"}) indicated that physical fatigue could be ameliorated according to swimming time extension with 4-week BD treatment. This phenomenon is consistent with a previous study, in which administration of arctigenin, a bioactive lignan found in BD, efficiently improved endurance running time on the treadmill in mice \[[@r36]\]. Another study confirmed that arctigenin efficiently enhanced the endurance swimming of sedentary SD rats by elevating the antioxidant capacity of the skeletal muscles via two antioxidant pathways: AMPK/PGC1α/PPARα in mitochondria and AMPK/p53/Nrf2 in the cell nucleus \[[@r40]\].

In exhaustive and high intensity exercise, excessive production of reactive oxygen species may induce oxidative stress and tissue damage \[[@r4]\], and the removal of excess free radicals may alleviate exercise-induced oxidative stress and body fatigue. Previous studies have reported that the free radical scavenging activity of BD is associated with its phenolic properties \[[@r9], [@r31]\]. Oral BD treatment may help reduce oxidative stress, decrease muscle damage, and improve exercise performance. Our data show that administration of BD extract extends endurance time to exhaustion of mice, therefore indicating that BD extract reduces fatigue and enhances exercise tolerance.

Glucose is transported to skeletal muscle to fulfil energy requirements, but anaerobic glycolysis occurs and results in lactate accumulation during high intensity exercise. Increased lactate levels lower pH, resulting in various biochemical and physiological side effects affecting glycolysis, phosphofructokinase, and muscular contractions caused by calcium ion release \[[@r6]\]. Levels of another important metabolite, ammonia, significantly increase with intense or prolonged exercise. Muscle fatigue is associated with the deamination of adenine nucleotides, and increased AMP deamination coincides with decreased phosphocreatine levels and pH, as well as failure of the contraction process. Peripheral and central fatigue levels are related to increased ammonia levels during exercise \[[@r7]\]. BUN is an important metabolite formed by protein degradation after intensive exercise \[[@r21]\]. Glucose, a breakdown product of tissue glycogen, is released as a circulating substrate and used as energy after intense exercise \[[@r13]\]. Exercise and muscle contractions increase glucose uptake by skeletal muscles via an insulin-independent mechanism \[[@r25]\]. During exercise, efficient utilization of glucose is an important index for performance maintenance. For incremental exhaustive exercise, several indicators are used to evaluate muscle and liver injury, such as CK \[[@r19]\]. Exercise performance is determined by energy storage and supply.

Catabolized fat and carbohydrates are considered the main sources of energy during exercise in skeletal muscles, and glycogen is the predominant source of glycolysis for energy production. The muscle content of glycogen is a limiting factor of prolonged exercise, and nutritional interventions could be beneficial for increasing or maintaining liver or muscle glycogen content, before or during exercise \[[@r14], [@r18]\]. Therefore, glycogen storage directly affects exercise ability \[[@r44]\]. Arctigenin, which is abundantly present in BD, can significantly increase Adenosine 5'-monophosphate (AMP)-activated protein kinase (AMPK) activation, regulating glycogen synthesis and efficiently increasing sedentary rodent treadmill endurance via AMPK phosphorylation enhancement \[[@r40]\]. Our results showed a significant increase in tissue glycogen storage with BD supplementation, which could enhance endurance performance.

In the present study, we observed the beneficial effects of BD using an exhaustive exercise challenge, and measured other physiological effects after 4 weeks of BD supplementation. However, intensive or exhaustive exercise will induce oxidative stress, such as the production of reactive oxygen species and free radicals, which injure cells and tissues \[[@r23], [@r27]\]. Such injury includes lipid peroxidation, which destroys membrane permeability, cell organization, and DNA integrity and function. Important enzymes such as LDH, CK, myoglobin, AST and ALT are also released into serum, and are considered biomarkers of tissue injury under high-intensity exercise challenge \[[@r34]\]. BD supplementation produces no side effects *in vivo* and exhibits potential for applications in measuring blood glucose, UA and hyperlipidemia, according to our *in vivo* data.

Histological data related to the pathological effects of BD is quite limited, especially with respect to the indicated bioactive doses. Our results also showed that the liver showed no lesions or pathological changes attributable to BD treatment ([Fig. 6](#fig_006){ref-type="fig"}). Hypertrophy and hyperplasia were not observed in heart cardiomyocytes or rhabdomyocytes of the gastrocnemius muscle. Furthermore, no lung inflammatory conditions were observed. Histological examination of organs showed no apparent damage in any mice.

In summary, here we provide evidence-based results to show that BD can improve physically-induced fatigue and elevate exercise performance in mice, as shown in the [Appendix Fig](#app_0A1){ref-type="fig"}. We found that BD supplementation significantly improved post-exercise physiological indicators and exercise performance, including grip strength and endurance time, by increasing muscle glycogen content. BD ameliorated exercise-related increases in levels of biomarkers such as lactate and ammonia. It decreases levels of CK, a muscle injury biomarker, and can be supplemented as optimized and reasonable doses for physiological benefits. Therefore, BD could help to ameliorate exercise-induced fatigue and safely contribute to the promotion of health.
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